Golsa Babapour

Dr. Golsa Babapour

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DPDae Yong Park
Dae Yong Park
YJYasser Jamil
Yasser Jamil
YAYousif Ahmad
Yousif Ahmad
TCTheresa Coles
Theresa Coles
HBHayden Barry Bosworth
Hayden Barry Bosworth
MSMarc D Samsky
Marc D Samsky
(1) Background: Cardiogenic shock (CS) is associated with high morbidity and mortality. Frailty and cardiovascular diseases are intertwined, commonly sharing risk factors and exhibiting bidirectional relationships. The relationship of frailty and non-acute myocardial infarction with cardiogenic shock (non-AMI-CS) is poorly described. (2) Methods: We retrospectively analyzed the National Inpatient Sample from 2016 to 2020 and identified all hospitalizations for non-AMI-CS. We classified them into frail and non-frail groups according to the hospital frailty risk score cut-off of 5 and compared in-hospital outcomes. (3) Results: A total of 503,780 hospitalizations for non-AMI-CS were identified. Most hospitalizations involved frail adults (80.0%). Those with frailty had higher odds of in-hospital mortality (adjusted odds ratio [aOR] 2.11, 95% confidence interval [CI] 2.03–2.20, p < 0.001), do-not-resuscitate status, and discharge to a skilled nursing facility compared with those without frailty. They also had higher odds of in-hospital adverse events, such as acute kidney injury, delirium, and longer length of stay. Importantly, non-AMI-CS hospitalizations in the frail group had lower use of mechanical circulatory support but not rates of cardiac transplantation. (4) Conclusions: Frailty is highly prevalent among non-AMI-CS hospitalizations. Those accompanied by frailty are often associated with increased rates of morbidity and mortality compared to those without frailty.

3 June 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
DPDae Yong Park
Dae Yong Park
BMBianca McLean
Bianca McLean
ZAZafer Akman
Zafer Akman
DLDarrick K. Li
Darrick K. Li
Golsa BabapourGolsa Babapour
Golsa Babapour
MNMichael G Nanna
Michael G Nanna
Background: Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) have traditionally received triple therapy (dual antiplatelet therapy and anticoagulation). More recent randomized trial evidence supports a strategy of double therapy (anticoagulant plus single antiplatelet agent), albeit after a brief triple therapy course. The safety of initiating double therapy immediately post‐PCI remains unclear. Methods and Results: This study analyzed real‐world prescribing patterns and outcomes of immediate double therapy versus initial triple therapy in patients with atrial fibrillation post‐PCI using the Vizient Clinical Database. Patients with atrial fibrillation undergoing PCI for myocardial infarction (2016–2023) were categorized into 2 groups: triple therapy (aspirin, P2Y12 [purinergic receptor P2Y, G‐protein coupled, 12 protein] inhibitor, and anticoagulant) or double therapy (anticoagulant and 1 antiplatelet agent) on day 1 post‐PCI. The primary outcome was in‐hospital mortality. Secondary outcomes included stent thrombosis, major bleeding, intracranial hemorrhage, and net clinical adverse events. Multivariable logistic regression and inverse probability of treatment weighting were used to compare outcomes. Among 29 226 patients, 16.3% received immediate double therapy on day 1 post‐PCI, whereas 83.7% received triple therapy. Adjusted analyses showed no significant differences in in‐hospital mortality (9.4% versus 9.2%, adjusted odds ratio [aOR], 1.05 [95% CI, 0.93–1.18]), major bleeding, intracranial hemorrhage, or net clinical adverse events. However, immediate double therapy was associated with higher odds of stent thrombosis (1.1% versus 0.8%; aOR, 1.48 [95% CI, 1.08–2.03]), particularly in patients with ST‐segment–elevation myocardial infarction (2.0% versus 1.3%; aOR, 1.46 [95% CI, 1.001–2.13]). Conclusions: Immediate double therapy post‐PCI is frequently used and appears safe for most patients with atrial fibrillation. Further studies are needed to identify high‐risk subgroups, including those with ST‐segment–elevation myocardial infarction, who may benefit from an initial short course of triple therapy.

1 April 2025 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
SISammudeen Ibrahim
Sammudeen Ibrahim
SSShreyas Singireddy
Shreyas Singireddy
CEChidubem Ezenna
Chidubem Ezenna
LALaura M. Romero Acero
Laura M. Romero Acero
ANArmin Nouri
Armin Nouri
MNMichael G Nanna
Michael G Nanna